Optimization of conditions related to Chrono-log platelet aggregation in feline whole blood.

Why and how to eliminate spontaneous platelet aggregation in blood measured by multiple electrode aggregometry

Studies of platelet aggregation are generally performed in p1ate1et-rich plasma(PRP) by the transmittance method. Recently, impedance aggregometry has been introduced which shows the platelet aggregability in whole blood. We compared the impedance aggregometry in whole blood with the transmittance method in PRP, with regard to collagen induced platelet aggregation. The aggregation rate in whole blood increased with increasing concentration of collagen, but remained unchanged in PRP. The factors which influence the platelet aggregation rate in whole blood were studied. CV-3988, that is the specific antagonist of PAF, acetylsalicylic acid (ASA) and phosphocreatine / creatine phosphokinase (CP/CPK) were used in order to evaluate the contribution of PAF, thromboxane and ADP in whole blood. CV-3988 dose-dependently inhibited platelet aggregation induced by collagen in whole blood, but did not inhibit the aggregation in PRP. ASA(10mM) inhibited the aggregation in whole blood incompletely too, but completely in PRP. And the inhibition of CP/CPK(CP/CPK : 1.5mM/50U/ml) was very weak in whole blood compared to that of other antagonists. The inhibitory effect of CV-3988 was investigated on the collagen induced platelet aggregation in whole blood which was pretreated with ASA ( 1 OmM ) and CP/CPK (1.5mM/50U/ml), resulting in a collagen induced aggregation in whole blood that was not completely inhibited. We conclude that there are some other different factors, which influence platelet aggregation in whole blood, in addition to thromboxane, ADP and PAF.

Platelets play a critical role in the pathophysiology of atherothrombotic disease. A pivotal event contributing to the understanding of platelet-dependent clot formation was the development of the platelet aggregometer in 1962.1 An aggregometer specifically measures the ability of platelets to adhere via glycoprotein IIb/IIIa (integrin αIIbβ3), and thousands of articles using this technique have been published, characterizing platelet function; however, the usefulness of these measurements remains unclear. Whereas the aggregometer and related techniques that measure platelet aggregation or glycoprotein expression have led to large amounts of data characterizing platelet function in various settings, the clinical importance of measurable differences in platelet function is still debated.2 The use of platelet function testing is established in rarer platelet abnormalities, such as the autosomal recessive bleeding disorder Glanzmann thrombasthenia,3 but no clear consensus has been reached on its usefulness for highly prevalent diseases caused by platelet-dependent thrombosis, such as myocardial infarction. A major factor for this discrepancy is that many of the platelet function defects that lead to bleeding are known to be caused by a single defect, whereas thrombosis in the setting of cardiovascular disease is presumed to be multifactorial. Article p 2490 The evolution of platelet function studies in various clinical settings has led to the realization that wide interindividual variability exists in the platelet activation response.4,5 What accounts for this variability? Only a few studies have systematically examined this question. Platelet function has been established as markedly dependent on the type of agonist used, the agonist concentration, and the concomitant use of antiplatelet therapy.6 In addition, in the large population-based Framingham Heart Study, O’Donnell and colleagues7 have demonstrated that heritable factors play a major role in determining platelet aggregation, as opposed to measured covariates. Less clear from the current literature is the direct …

Electrical impedance vs. light transmission aggregometry: Testing platelet reactivity to antiplatelet drugs using the MICELI POC impedance aggregometer as compared to a commercial predecessor

Upon erosion and rupture of an atherosclerotic plaque, collagen and serotonin (5-hydroxytyramine [5-HT]) induce a process of simultaneous platelet aggregation and vasoconstriction. Simultaneous inhibition of these pathophysiological processes, attainable by 5-HT inhibition, is a potential drug target and could offer an attractive treatment modality. The availability of a reliable and accurate test to measure inhibition of 5-HT-induced platelet aggregation would facilitate the rational development of such new compounds. Therefore, we developed a validated method to measure the additive effect of 5-HT on platelet aggregation in human whole blood after an initial induction by a low-concentration collagen, using impedance aggregometry. This method is feasible to measure 5-HT-induced platelet aggregation in whole blood for the evaluation of promising platelet aggregation inhibitors possessing 5-HT antagonistic activity. The availability of this method will support and stimulate selective 5-HT antagonism as effective management of thrombosis.

Multiple electrode aggregometry and P2Y12 antagonists

EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin

Although cross-talks between platelets and other blood cells are important in vivo, laboratory platelet aggregation tests have been performed mainly with the use of platelet-rich plasma (PRP) as samples. Methods that enable an efficient and sensitive detection of platelet aggregates in whole blood are being developed. A flow cytometer equipped with an imaging device, the flow imaging cytometer 2 (FIC2), was used to detect platelet aggregates in whole blood. The FIC2 provides a resolution that is high enough to differentiate platelet aggregates from single platelets or other blood cells. Epinephrine elicited platelet aggregate formation in hirudin plus argatroban-treated whole blood, but not in PRP. The reconstitution study revealed that a small amount of adenosine diphosphate (ADP) from erythrocytes may play an important role in epinephrine-induced platelet aggregation (in whole blood), through mediation of P2Y1 receptors. When the inhibitory effect of beraprost, an antiplatelet agent, on platelet aggregation was assessed, analysis of whole blood samples with FIC2 proved to be the most sensitive among the methods available. FIC2 is a promising device for detection of platelet aggregates in whole blood, with wide basic and clinical applications.

Development of a competititve immunometric enzyme-linked immunosorbent assay (ELISA) for the major human urinary metabolite of 15-F 2T-isoprostane, a noninvasive biomarker for oxidant stress

An in vitro method for screening anti-platelet agents using a microchannel array flow analyzer

Erythropoietin treatment is known to correct anemia and to improve hemostasis. Since platelets may contribute to thromboembolic complications, we assessed platelet aggregation in whole blood and platelet-rich plasma from chronically hemodialyzed patients treated with erythropoietin and evaluated in vitro effects of this drug on aggregatory responses of uremic and normal platelets. Recombinant human erythropoietin was given to uremic patients at a dose of 2,000 IU subcutaneously three times a week. Platelet aggregation in whole blood and platelet-rich plasma was induced by collagen, ADP, arachidonic acid, and ristocetin. In uremic patients, erythropoietin therapy resulted in an enhancement of platelet sensitivity to various agonists, particularly in platelet-rich plasma, reaching values comparable to those of healthy volunteers. In vitro studies we were unable to show any direct effect of erythropoietin, used at concentrations that occurred post intravenous administration, on platelet aggregation both in whole blood and in platelet-rich plasma.

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.

Exercise-induced changes in platelet aggregation; a comparison of whole blood and platelet rich plasma techniques

Although the viscoelastic testing (VET) method was first described by Hartert1 more than seven decades ago, its application as point-of-care (POC) instrumentation in the surgical and trauma settings is relatively recent. Short turnaround times and delivery of results in real time provide clinicians with a relevant and rapid global assessment of hemostasis. Recent advances have further simplified and parsed out the multiple components of hemostasis and clotting to assess for large alterations in clotting factors, inhibitors, fibrinogen, and fibrinolysis. As such, many have reported the use of various VET variables in managing perioperative bleeding and have developed transfusion protocols for specific blood products and pharmacological intervention based on these testing results.2-6 A summary of the VET method is discussed in previous articles within this supplementary edition. This article specifically focuses on the use of VET in the context of platelet function tests (PFTs), and its advantages and limitations compared to other PFT in various clinical settings. For his invention Hartert coined the designation thromboelastography. For the sake of this review we will use the term thromboelastography (TEG) to designate the principle of a testing system in which a sample of whole blood is introduced into a cup that contains a pin or cylinder. Initially the pin and the cup move relative to one another in clockwise and counterclockwise rotations. After activation, fibrin and platelet (PLT) strands form between the cup and the cylinder resulting in an inhibition of motion or an impedance. This impedance or viscoelastic element is quantified and displayed as an optical signal (Figure 1 and Table 1). Currently there are two types of VET, the original form based on the cup-and-pin technology and the more recent form based on ultrasound. In fixed-motion TEG the cup moves, while the detection of altered viscoelasticity and the elastic coupling are on the side of the pin. Fixed-motion TEG has the disadvantage of being sensitive to shock and vibrations. Each dislocation of a device necessitates a calibration of the machine. In elastic-motion TEG, generally, the pin is motile and the site of detection and elastic coupling. There is one exception to this rule with the ClotPro technology where the cup is motile and detection and elastic coupling are linked to the cup. The elastic-motion technology is relatively vibration and shock resistant. Devices are readily transportable. To improve on fixed-motion technology, producers developed resonance viscoelastography, where alterations in clot viscoelastic properties are assessed by ultrasound. Clots are made to resonate by ultrasound stimulation. Wave modeling allows for analysis of viscoelastic properties. "Platelet function" can be defined as a complex process including all activities mediated by PLTs or by PLT-derived products. Before elaborating on how PLT function integrates into VET, we shall focus on relevant aspects of PLT function. In its simplest sense, PLT function can be categorized into energy-independent vs energy-dependent processes. The classic energy-independent process is PLT agglutination in the presence of the antibiotic ristocetin. Under basal in vivo conditions, the PLT von Willebrand factor (VWF) receptor, glycoprotein Ib (GPIb) cannot interact with circulating plasmatic VWF. However, ristocetin interacts with PLTs and VWF and can promote agglutination in a passive VWF-dependent mechanism. As such, this interaction has been used in in vitro assays for diagnostic purposes.7 In contrast, the energy-dependent mechanisms refer to the biomechanical processes that are governed by signal transduction pathways, such as glycolysis and oxidative phosphorylation, as well as the ATP/ADP stored in dense granules. These energy sources are critical to support and sustain energy intensive processes requiring PLT cytoskeletal arrangements, such as adhesion, spreading, aggregation and contraction.8, 9 In vivo, one can define different stages of PLT activation, namely the initiation phase with adhesion, the extension phase with secretion, the consolidation phase with aggregation and clot retraction, and finally the termination and elimination phases with fibrinolysis.10-12 It is important to note that each phase is its own series of multi-step processes that occur simultaneously and may subsequently repeat over time (Figure 2). In the presence of endothelial damage single PLTs may adhere to the newly exposed adventitial collagen fibers and freshly deposited VWF. Through "outside-in" signaling, mediated by the stimulation of the PLT surface collagen receptors and GPIb (VWF receptors), PLT activation is initiated. Through various signaling pathways, soluble and solid mediators are produced and secreted for further recruitment of PLTs to the site of injury and propagation of coagulation. During PLT activation, a flip-flop of the inner leaflet phospholipids into the outer leaflet provides a negatively charged and activated surface on which coagulation factors can bind and generate thrombin in a localized fashion. Coagulation is further propagated by the tissue factor–rich, PLT-derived microparticles generated and released into circulation. The membrane-bound and eventual activated coagulation factors lead to the generation of thrombin (FIIa). In addition to its role as activator of multiple coagulation factors, circulating blood cells, and cells located in the blood vessel wall, thrombin is also a key activator of PLTs. The thrombin-dependent PLT activation is mediated by thrombin's specific PLT receptor, the protease activator receptors (PARs).13, 14 The binding of ligands and/or activators to PLT surface receptors play a major role in PLT function. Receptors have high specificity for their respective ligands, which can be solutes, such as thromboxane A2 (TXA2) and adenosine diphosphate (ADP); VWF; or solids, such as collagen. The interaction of the ligands with their specific receptor results in the outside-in activation of PLTs, with each receptor associated with either a single particular or a multiple signaling pathway, forming intricate intracytoplasmic networks. For instance, as a safeguard against any basal level PLT aggregation, in its resting state the GPIIb/IIIa receptor does not bind any ligand. Once the signaling threshold for activation is reached, an inside-out activation occurs, and with subsequent allosteric changes of the PLT GPIIb/IIIa receptor, there is increased affinity for fibrinogen/fibrin binding. The resultant PLT aggregation is defined by this GPIIb/IIIa–fibrinogen interaction culminating in multiple PLTs binding the same fibrinogen molecule and subsequent bridging of adjacent PLTs. The thrombin generated in the immediate vicinity will transform the PLT-bound fibrinogen into fibrin followed by the stabilization of the primary fibrin clot by activated coagulation factor XIII (FXIIIa).15 A main contributor to PLT function are the PLT granules, whose secreted contents play roles in the amplification of PLT activation, the recruitment of circulating PLTs into aggregates, and clot stabilization. Alpha-granules contain adhesion proteins such as fibrinogen and VWF as well as coagulation and fibrinolytic factors, cytokines, and growth factors. Dense granules contain activating nucleotides such as ADP and ATP, serotonin, histamine, pyrophosphates, and divalent cations.10, 13 No PFT can truly recapitulate the in vivo environment and anatomy of the differing arterial, capillary, and venous vascular beds and the relationship of single PLTs to the vessel (taking into account variables such as shear rate, relative proximity to vessel wall, and the underlying endothelium). Of note, these underlying mechanisms promoting PLT aggregation and clot formation can vary with shear rate conditions. Under the relatively low shear conditions, typically found in the low flow/pressure of venous vascular beds, coagulation factors dominate the hemostatic processes. With endothelial damage, PLT adhesion and aggregation are primarily influenced by the supporting role of fibrinogen, with its binding of PLTs via GPIIb/IIIa. Contrast this to the high-shear conditions of the arterial vascular system, wherein VWF plays the more prominent role and PLT aggregation becomes more heavily influenced by the VWF engagement of GPIb.16 Although these underlying mechanisms are key concepts in defining "platelet function," no one assay completely replicates the full complexity of in vivo PLT activity. For PFT, one may consider PLT function sensu stricto as the processes involved in PLT aggregation. However, as it shall become apparent, disregarding or discounting other components of PLT function can result in possible misinterpretation or misunderstanding of the underlying PLT defect or dysfunction. A multitude of systems assess PLT functions in vitro, most of which evaluate PLT aggregation (Figure 2). Light transmission aggregometry (LTAl; turbidimetric-based assay) and whole blood PLT aggregometry (WBA; impedance-based aggregometry assay) measure low-shear, GPIIb/IIIa-dependent PLT-to-PLT aggregation in response to agonists in PLT-rich plasma and whole blood, respectively. Although considered the gold standard in PLT defect diagnostics, with standardized guidelines for sample preparation, agonist concentration, and interpretation of results,17-20 LTA is considered labor- and time-consuming and difficult to standardize in practice. Despite omitting the labor-intensive step of PLT-rich plasma preparation, WBA continues to be plagued by large sample volumes and time commitments. As an assay supplement to LTA or WBA, lumiaggregometry evaluates dense granule secretion of activated PLTs in response to various agonists. Secretion is measured by detecting luminescence emitted when secreted ATP reacts with a bioluminescent reagent. The multiple-electrode aggregometry (MEA) method, a cartridge-based POC version of WBA touting minimal technical training, still requires skilled interpretation of the assay result. Its measurements are based on a combination of PLT activation and adhesion of activated PLTs to a surface. As with LTA and WBA, MEA utilizes multiple agonists and may be suitable for diagnosis of PLT dysfunction or for monitoring anti-PLT therapy, but as with other PLT aggregation tests, MEA is dependent on PLT count.21-24 With increased interest in monitoring anti-PLT therapy, studies have compared newer platforms, such as VerifyNow and TEG-PM, to MEA as a proxy for the gold-standard LTA. The whole blood, flow-dependent PFA-100/200 assays quantify adhesion/aggregation by measuring the time necessary for a PLT plug to occlude an aperture within a biologically active membrane (collagen–epinephrine vs collagen–ADP coated). Although considered a simple and rapid test, it requires a minimum hematocrit and a minimum PLT count,25 both of which are frequently unmet in the perioperative or acute bleeding setting, thereby limiting its applicability. This system is sensitive to VWF concentration and activity,26 and these aspects must be considered when evaluating PLT function deficits. VerifyNow is a turbidimetric, cartridge-based POC device assessing whole blood PLT aggregation upon fibrinogen-coated beads in response to agonists, whose measurement is proportional to the number of activated GPIIb/IIIa receptors. Modified versions of the assay are sensitive to the PLT response to aspirin or P2Y12 receptor blockers. As the VerifyNow P2Y12 assay blocks P2Y1-mediated aggregation it can measure P2Y12-mediated aggregation. This contrasts with standard PLT aggregometry, wherein the agonist ADP is used without inhibitors and both P2Y1- and P2Y12-mediated aggregation are measured.27 This may explain observed discrepancies between VerifyNow and standard PLT aggregometry when assessing clopidogrel responses.28-30 Monitoring anti-PLT therapy in cardiac patients with VerifyNow had been a low-level recommendation.31 Large prospective randomized controlled trails had failed to demonstrate the use of POC assessments of PLT function in reducing ischemic events and did not provide support for changing anti-PLT therapy based on these tests.32-35 Although initial studies showed that the utilization of VerifyNow for PLT transfusion guidance led to improvement in measured PLT activity for patients with intracranial hemorrhage,36 larger studies focusing on intracranial bleed patients on COX inhibitors found an increase in the odds of death or dependence at 3 months in those who had PLT transfusion compared to the standard care group.37 Few patients on P2Y12 inhibitors were included in the study, and results may not be generalizable to that population. Such scenarios demonstrate the need of large well-designed clinical trials to validate extrapolations of in vitro PLT function studies. The POC Plateletworks also assesses PLT aggregation by comparing the baseline count of nonaggregated PLTs in agonist-untreated samples to those treated with agonists such as collagen, ADP, and arachidonic acid. The degree of PLT aggregation tends to be higher in Plateletworks in comparison to that of LTA, with speculation that the single PLT counting of Plateletworks is more sensitive to microaggregation as opposed to the LTA-measured macroaggregation.38, 39 Evaluation for use in clinical practice to monitor the use of the anti-PLT drugs such as aspirin and clopidogrel39-41 demonstrated good agreement with LTA in acute care settings. Unfortunately, due to a measurement window of only a few minutes, the test has been utilized primarily within surgical settings and clinical data are lacking on its effect on clinical outcomes.42 Flow cytometry's utilization of agonists and antibodies against glycoproteins, such as P-selectin, activated GPIIb/IIIa, and GPIb, profiles structural and functional PLT variables of 1000 of individual PLTs. Granule secretion and aggregation are quantified by gating the amount of P-selectin and activated GPIIb/IIIa receptors on membranes.43-45 Primarily used for research, assessment of PLT surface glycoprotein expression has potential clinical applications in monitoring GPIIb/IIIa antagonist therapy and diagnosing glycoprotein deficiencies or storage pool disease, among other applications.46 Viscoelastic testing is often referred to as a global assay of hemostasis. VET analyzes changes in the viscoelastic forces during clot formation upon the addition of activators or inhibitors to whole blood (Table 2). The VET method is discussed extensively in previous modules within this supplementary edition and we refer to those articles for detailed description. Polybrene Cyclochalasin D Polybrene Tranexamic acid Reptilase FXIIIa ADP Reptilase FXIIIa Arachidonic acid Cytochalasin D, GPIIb/IIIa antagonist Polybrene Polybrene Abciximab By design there is a major difference in VET vs in vivo physiology. In VET or in vitro, there is no contribution of the vascular system. Furthermore, activation occurs inversely, in that initially secondary hemostasis is activated either intrinsically or extrinsically before subsequently primary hemostasis gets activated—mostly by thrombin. In vivo, the sequence of cardinal events is endothelial damage, VWF deposition, PLT adhesion, outside-in signaling, secretion, inside-out signaling, aggregation, clot retraction, and fibrinolysis. In summary in vitro the chain of events is secondary hemostasis, primary hemostasis, and fibrinolysis, while in vivo, vascular hemostasis precedes primary and secondary hemostasis before fibrinolysis sets in. In VET, PLT function is assayed as a maximal stimulation or an all or nothing response. This is due to the design of the testing systems. After recalcification of the citrated whole blood sample, activation of secondary or plasmatic hemostasis by potent activators of the intrinsic or extrinsic system will lead to traces of thrombin being generated followed by a massive thrombin "burst." The thrombin burst will strongly stimulate PLTs leading to a maximal PLT signal. This maximal signal will correlate with the PLT concentration.47 However, this signal will not correlate with PLT function. Thus the VET signal will not be influenced by the presence or absence of antiaggregants therapy, because thrombin-induced and PAR-mediated outside-in signaling bypasses other activation routes and always produces a maximal response. PAR-mediated PLT activation represents a form of emergency bypass to all other signal transduction pathways, in situations where rapid and complete PLT activation is necessary. This kind of all-or-nothing activation situation is not sensitive to cofactors including antiaggregants such as aspirin or P2Y12 inhibitors. The only PLT inhibitor or situation to which this setting is sensitive to are GPIIb/IIIa inhibitors or defects in that receptor including Glanzmann thrombasthenia. In these cases, PLTs can no longer activate inside out, preventing multiple PLTs from interacting with fibrinogen or fibrin molecules leading to a reduced PLT signal in VET. Eli Cohen, the inventor of TEG and TEG PLT mapping (TEG -PM), had the idea of activating citrated whole blood samples with an array of different activators and inhibitors.48 He used a kaolin- and calcium-activated TEG to generate a maximum signal. This signal is composed of a fibrinogen (and FXIIIa) contribution and a PLT contribution. With the use of a cocktail of activators, VET was sensitized to PLT activators weaker than thrombin. This cocktail consisted of (a) reptilase (or botrobotoxin)—a snake poison that activates fibrinogen to fibrin but does not lead to activation of the thrombin-dependent PAR receptors on PLTs; (b) FXIIIa—to stabilize the fibrin clot by generating stable covalent bonds between fibrin monomers; and (c) heparin—which neutralizes any generated thrombin. Then, by adding either arachidonic acid, an activator of the TXA2 receptor/cyclooxygenase pathway (inhibited by aspirin), or ADP, an activator of the P2Y12 receptor (inhibited by the class of P2Y12 inhibitors including clopidogrel, prasugrel, and others), he generated tests sensitive to cyclooxygenase and P2Y12 inhibitors. Platelets play a key role in fibrinolysis, and fibrinolysis can be detected by VET. PLTs represent an activated surface suitable for the assembly of the entire plasminogen activator system. Furthermore, PLTs secrete plasmin in an autocrine fashion and bind it to their surface. The latter aspect is relevant in the sense that free plasmin is prone to inhibition through its primary plasmatic inhibitor alpha2 antiplasmin, whereas PLT-bound plasmin is not. Plasmin has also been reported to cleave GPIIIa, leading to a dysfunctional PLT state late on in the process of hemostasis. High numbers of PLTs in a clot lead to stable clots, whereas PLT-poor clots are more prone to fibrinolysis.49 Plasminogen activator inhibitor 1 can bind to the PLT surface, leading to inhibition of fibrinolysis early on in coagulation.50, 51 Thus, whenever fibrinolysis becomes apparent in VET, this too can be interpreted as a manifestation of PLT function. Most clinical studies have focused on global hemostasis monitoring and have evaluated the clinical usefulness of VET for the prediction, diagnosis, and transfusion guidance in coagulopathic-based bleeding in trauma, obstetrics, liver, and cardiac perioperative settings. Some have focused on the application of VET-guided transfusion strategies to reduce the use of blood products and improve morbidity in bleeding patients.3-6 Less is known on VET use in the evaluation of PLT function in these settings,52-55 because standard VET tracings give minimal information on PLT function's contribution to clot strength. Meta-analyses have been mixed, with at least two describing a significant effect of VET on the proportion of patients transfused with PLTs.52, 54, 56 There are data that suggest that the two platforms, Sonoclot and Quantra QPlus, can assay aspects of PLT function.57, 58 As detailed, and not unlike other VET systems, these two systems also fall under the all-or-nothing principle of thrombin-activated tests, wherein the resulting implications include a lack of sensitivity to antiaggregants including aspirin and P2Y12 inhibitors. However, when one defines PLT function solely by the interaction of the PLT's fibrinogen receptor with its substrate, then these VET systems may indeed be able to report on a limited aspect of PLT function–related The by and and the and is evaluated based on clot with the that clot occurs with PLT while clot is when the fibrinogen with and is from the in the extrinsic pathway activated treated with Unfortunately, only a of and perioperative studies have focused on the clinical and of or measurements in PLT function PLT were found to be associated with Sonoclot measurements in a prospective study, which compared TEG to Sonoclot variables in cardiac It was that the degree of a that such a be of an immediate POC in vitro studies found and influenced by PLT and of the to PLT was in studies are to validate PLT function and is not a of PLT early that Quantra with function demonstrated by to the and associated for PLT studies are to for potential clinical use by first assessing PLT contribution to clot in patients cardiac and with studies comparing its to those of other in vitro studies have assessed to monitor PLT function and GPIIb/IIIa such had found to be to PLT aggregometry in its to pharmacological GPIIb/IIIa inhibition by studies are to demonstrate potential use in assessing the of anti-PLT In a prospective wherein Quantra was compared to TEG for use in transfusion for patients cardiac it had been described that the P2Y12 receptor inhibitor therapy and may the clinical need for PLT is because these early and in vitro studies not coagulation changes in clinical trials are still to evaluate both and in monitoring PLT function in the trauma, and settings. The of VET for anti-PLT detection of and have been However, standard VET the major in their to measure PLT adhesion and to the effect of aspirin or P2Y12 receptor due to the thrombin generation as a response to the This response any to the inhibition of the TXA2 receptor/cyclooxygenase and P2Y12 receptor at only the detection of GPIIb/IIIa In of the increased clinical use of P2Y12 inhibitors and the of previous VET to their studies the of for anti-PLT monitoring and its use in bleeding or transfusion have compared to other PFT and evaluated in its to but there have been clinical For two prospective focusing on bypass patients described PLT inhibition TEG-PM, had to correlate with or blood In contrast, a prospective of bypass patients may as a for PLT inhibition as the PLT function measured by was associated with increased transfusion to other aspects including and transfusion the of testing may be key to the in these The studies that PLT function found a with the primary or transfusion whereas those that did not. Furthermore, a factor may be that bypass can be associated with a PLT as by that may or may not be associated with an increased bleeding in evaluating for its in monitoring anti-PLT therapy in trauma, and agreement and between and other PFT as and have been larger prospective studies are to the clinical of for In are to the many role in hemostasis. PLT function may be defined in a of and the activation and inhibition of a of As such there is no standard to define PLT function and no gold standard in the VET PLT between different VET and the of PFT a The of VET and its relative turnaround time have led to increased utilization among clinical for the evaluation of anti-PLT effect on hemostasis during trauma or surgical situations or in the of for upon the of the Although most VET measuring PLT function correlate with PLT many low and for PLT due to the thrombin activation of PLTs through the receptor, a that standard anti-PLT cannot be detected standard VET. VET ADP or arachidonic acid may the assessment of the of P2Y12 inhibitors and clinical trials are to evaluate these can the inhibition of the anti-PLT of and improve clinical The their to from the and from for the real time of a whole blood no potential of has from and no other potential of

Current methods of assessing platelet function: relevance to transfusion medicine